地夸磷索钠滴眼液对中重度干眼患者眼表状况和视觉质量的影响

doi:10.3760/cma.j.cn115909-20201029-00418

摘要
图/表
参考文献(22)
相关文章 (15)

全文: PDF 3311KB HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

文章导读

摘要目的：评价3%地夸磷索钠滴眼液对中重度干眼患者眼表状况和视觉质量的改善效果。方法：前瞻性临床研究。收集2019年9月至2020年8月在武汉大学人民医院眼科门诊就诊的中重度干眼患者78例（78眼），将其按随机数字表法随机分为人工泪液组38例（38眼）和地夸磷索钠滴眼液组40例（40眼），人工泪液组使用人工泪液点眼3次/d，地夸磷索钠滴眼液组使用3%地夸磷索钠滴眼液点眼6次/d和人工泪液3次/d，治疗1个月后观察疗效。2组数据比较采用独立样本t检验，性别差异使用卡方检验，组内治疗前后指标评分比较采用配对样本t检验，多重比较采用Bonferroni检验。各项参数间相关性分析使用Spearman相关性分析。结果：点眼1个月后，2组患者眼表状况及视觉质量均有所改善，地夸磷索钠组的泪膜破裂时间（BUT）、泪河高度、泪液分泌试验、角膜荧光染色（FL）和泪膜客观散射指数（TF-OSI）较人工泪液组比较效果更优，差异均有统计学意义（t=2.613，P=0.029；t=8.498， P=0.001；t=4.082，P=0.015；t=15.06，P<0.001；t=5.021，P=0.007）。2组使用前后的TF-OSI与BUT、调制传递函数截止频率呈负相关（r=-0.298，P=0.045；r=-0.478，P=0.033；r=-0.478，P=0.004； r=-0.399，P=0.006），且地夸磷索钠组TF-OSI与干眼问卷调查得分、FL呈正相关（r=0.479， P=0.035；r=0.254，P=0.027）。结论：地夸磷索钠滴眼液联合人工泪液可以有效改善中重度干眼的临床症状及体征，并能明显提高患者的视觉质量，效果优于单用人工泪液。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ： , 中重度干眼, P2Y2受体, 泪膜, 视觉质量, 泪膜客观散射指数

Abstract： Objective: To evaluate changes in the ocular surface status and the visual quality in patients with moderate to severe dry eyes before and after treatment with 3% diquafosol sodium eye drops. Methods: In this prospective clinical study, a total of 78 patients (78 eyes) with moderate to severe dry eye were included from the ophthalmic outpatient department of Renmin Hospital of Wuhan University from September 2019 to August 2020. Patients were randomly divided into two groups based on the criteria. In the artificial tear group, 38 patients (38 eyes) were treated with artificial tear drops for 3 s/d; in the diquafosol sodium group, 40 patients (40 eyes) were treated with diquafosol sodium for 6 s/d and artificial tear for 3 s/d. The therapeutic effect was observed 1 month after treatment. The data were analyzed by sample t test, Chi-square and Spearman correlation. Results: After 1 month of treatment, the two groups of patients had improved, and the effect in the diquafosol sodium group was better than that in the artificial tears group for break-up time (BUT), tear meniscus height, Schirmer Ⅰ test, corneal fluorescein staining (FL) and the tear film objective scatter index (TF-OSI) (t=2.613, P=0.029; t=8.498, P=0.001; t=4.082, P=0.015; t=15.06, P<0.001; t=5.021, P=0.007). TF-OSI was negatively correlated with BUT and Modulation transfer function cut off before and after use in the two groups (r=-0.298, P=0.045; r=-0.478, P=0.033; r=-0.478, P=0.004; r=-0.399, P=0.006), and TF-OSI was positively correlated with the dry eye questionnaire score (OSDI) and FL in the diquafosol sodium group (r=0.479, P=0.035; r=0.254, P=0.027). Conclusions: Diquafosol sodium combined with artificial tears can effectively improve the clinical symptoms and signs of moderate to severe dry eyes, and can effectively improve the visual quality of patients. This improvement is better than treatment with artificial tears alone.

Key words： moderate and severe dry eyes P2Y2 receptor tear film visual quality objective scattering index of tear film

收稿日期: 2020-10-29

PACS:

基金资助:国家自然科学基金（81770899）

通讯作者: 杨燕宁（ORCID：0000-0001-8419-6706），Email：ophyyn@163.com

引用本文:

王杨黄钰清杨燕宁. 地夸磷索钠滴眼液对中重度干眼患者眼表状况和视觉质量的影响[J]. 中华眼视光学与视觉科学杂志, 2021, 23(5): 329-335. Yang Wang, Yuqing Huang, Yanning Yang. Effect of Diquafosol Sodium on the Ocular Surface and the Visual Quality of Patients with Moderate to Severe Dry Eyes. Chinese Journal of Optometry Ophthalmology and Visual science, 2021, 23(5): 329-335. DOI: 10.3760/cma.j.cn115909-20201029-00418

链接本文:

https://www.cjoovs.com/CN/10.3760/cma.j.cn115909-20201029-00418 或 https://www.cjoovs.com/CN/Y2021/V23/I5/329

[1]	Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS Ⅱ epidemiology report. Ocul Surf, 2017, 15(3): 334-365. DOI: 10.1016/j.jtos.2017.05.003.
[2]	Song P, Xia W, Wang M, et al. Variations of dry eye disease prevalence by age, sex and geographic characteristics in China: A systematic review and meta-analysis. J Glob Health, 2018, 8(2): 020503. DOI: 10.7189/jogh.08.020503.
[3]	Rathi VM, Sangwan VS. Prevention, diagnosis & management of dry eye in South Asia. Community Eye Health, 2017, 30(99): S3-S4.
[4]	Utsunomiya T, Kawahara A, Hanada K, et al. Effects of diquafosol ophthalmic solution on quality of life in dry eye assessed using the dry eye-related quality-of-life score questionnaire: Effectiveness in patients while reading and using visual display terminals. Cornea, 2017, 36(8): 908-914. DOI: 10.1097/ICO.000000000000124.1.
[5]	Inoue Y, Ochi S. Effects of 3% diquafosol sodium ophthalmic solution on higher-order aberrations in patients diagnosed with dry eye after cataract surgery. Clin Ophthalmol, 2017, 11: 87-93. DOI: 10.2147/OPTH.S122542.
[6]	Wu D, Chen WQ, Li R, et al. Efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye: A systematic review of randomized clinical trials. Cornea, 2015,34(6): 644-650. DOI: 10.1097/ICO.0000000000000429.
[7]	中国干眼专家共识: 定义和分类(2020 年). 中华眼科杂志, 2020, 56(6): 418-422. DOI: 10.3760/cma.j.cn112142-20200316- 00190.
[8]	万珊珊, 杨燕宁, 袁静, 等. 眼表综合分析仪评价干眼患者相关指标的临床分析. 中华眼视光学与视觉科学杂志, 2015, 17(3): 171-175. DOI: 10.3760/cma.j.issn.1674-845X.2015.03. 010.
[9]	严江波, 杨燕宁, 黄林英, 等. 双通道技术评估睑板腺功能障碍性干眼患者的视觉质量. 中华眼视光学与视觉科学杂志, 2015, 17(11): 668-672. DOI: 10.3760/cma.j.issn.1674- 845X.2015.11.007.
[10]	Watanabe H. Medical treatment for dry eye in Japan. Invest Ophthalmol Vis Sci, 2018, 59(14): DES116-DES120. DOI: 10.1167/iovs.18-24130.
[11]	Koh S. Mechanisms of visual disturbance in dry eye. Cornea, 2016, 35(Suppl 1): S83-S88. DOI: 10.1097/ICO. 0000000000000998.
[12]	Denoyer A, Rabut G, Baudouin C. Tear film aberration dynamics and vision-related quality of life in patients with dry eye disease. Ophthalmology, 2012, 119(9): 1811-1818. DOI: 10.1016/j.ophtha.2012.03.004.
[13]	晋秀明, 章悦. 关注干眼的系统治疗方法. 中华实验眼科杂志, 2019, 37(3): 218-223. DOI: 10.3760/cma.j.issn.2095-0160. 2019.03.011.
[14]	阳雪, 李莹. 弹性软硅胶泪点塞治疗对重度干眼的短期疗效及对患者心理状况影响的研究. 中华眼科杂志, 2018, 54(6): 437-444. DOI: 10.3760/cma.j.issn.0412-4081.2018.06.010.
[15]	Zhang J, Yan X, Li H. Analysis of the correlations of mucins, inflammatory markers, and clinical tests in dry eye. Cornea, 2013, 32(7): 928-932. DOI: 10.1097/ICO.0b013e3182801622.
[16]	Yokoi N, Kato H, Kinoshita S. Facilitation of tear fluid secretion by 3% diquafosol ophthalmic solution in normal human eyes. Am J Ophthalmol, 2014, 157(1): 85-92. DOI: 10.1016/ j.ajo.2013.09.009.
[17]	Koh S, Maeda N, Ikeda C, et al. Effect of diquafosol ophthalmic solution on the optical quality of the eyes in patients with aqueous-deficient dry eye. Acta Ophthalmol, 2014, 92(8): e671-e675. DOI: 10.1111/aos.12443.
[18]	Koh S, Ikeda C, Takai Y, et al. Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye. Jpn J Ophthalmol, 2013, 57(5): 440-446. DOI: 10.1007/ s10384-013-0251-y.
[19]	Koh S, Tung CI, Inoue Y, et al. Effects of tear film dynamics on quality of vision. Br J Ophthalmol, 2018, 102(12): 1615-1620. DOI: 10.1136/bjophthalmol-2018-312333.
[20]	Hori Y. Secreted Mucins on the ocular surface. Invest Ophthalmol Vis Sci, 2018, 59(14): DES151-DES156. DOI: 10.1167/iovs.17-23623.
[21]	Fukuoka S, Arita R. Tear film lipid layer increase after diquafosol instillation in dry eye patients with meibomian gland dysfunction: A randomized clinical study. Sci Rep, 2019, 9(1): 9091. DOI: 10.1038/s41598-019-45475-7.
[22]	Schmidl D, Schmetterer L, Witkowska KJ, et al. Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease. Cornea, 2015, 34(4): 421-426. DOI: 10.1097/ICO.0000000000000358.